Dmytro Fedkov

Chief Medical Officer

Germany

Research Interests

Explore related searches

Professors in Germany

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Dmytro Fedkov is the Chief Medical Officer at Midaia GmbH in Germany. His research areas include inflammatory arthritis, with a focus on disease activity, mobile health interventions, and treatment response prediction. He has authored several recent articles examining the impact of lifestyle changes on disease management and the efficacy of mobile applications in clinical settings. Additionally, he explores novel educational formats in clinical training.

Articles (10)

Year:

2024

Year:

2024

Year:

2022

Year:

2021

Year:

2020

Year:

2020

Year:

2020

Year:

2020

Year:

2020

Year:

2020

Collaborators (1)

Sebastian Kuhn

Full Professor / Director of the Institute

Philipps-Universität Marburg Fachbereich Medizin

GERMANY

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Dmytro Fedkov

Research Interests

Explore related searches

Contact this professor

About

Articles (10)

Disease activity and fatigue in inflammatory arthritis patients with different dietary preferences: a retrospective exploratory cross-sectional study

Effect of Lifestyle Counselling via a Mobile Application on Disease Activity Control in Inflammatory Arthritis: A Single-Blinded, Randomized Controlled Study

Efficacy and safety of a mobile app intervention in patients with inflammatory arthritis: a prospective pilot study

Experience in introducing a new interactive format of lectures at clinical departments and the attitude of students towards them

Bone turnover biomarkers, disease activity, and MRI changes of sacroiliac joints in patients with spondyloarthritis

Clinical presentation, imaging and response to interferon-alpha therapy in Erdheim–Chester disease: case-based review

Clinical presentation, imaging and response to interferon-alpha therapy in Erdheim-Chester disease: case-based review

Fenebrutinib versus Placebo or Adalimumab in Rheumatoid Arthritis: A Randomized, Double-Blind, Phase II Trial (ANDES Study).

Fenebrutinib Versus Placebo or Adalimumab in Rheumatoid Arthritis: A Randomized, Double-Blind, PhaseIITrial

TREATMENT RESPONSE PREDICTION IN PATIENTS WITH RHEUMATOID ARTHRITIS. Review

Collaborators (1)

Sebastian Kuhn

Make your next move.